Latest News and Press Releases
Want to stay updated on the latest news?
-
SHANGHAI, SAN FRANCISCO and CAMBRIDGE, Mass., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical...
-
SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global...
-
Topical therapy with ZL-1102 resulted in clinical improvement in local PASI score, erythema and scaling, target lesion size, and responder rates in patients with mild-to-moderate chronic plaque...
-
SUL-DUR first to achieve statistical non-inferiority in 28-day all-cause mortality in carbapenem-resistant Acinetobacter (CRAB) patients Statistically significant difference in clinical cure at Test...
-
SHANGHAI, SAN FRANCISCO, and CAMBRIDGE, Mass., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global...
-
SHANGHAI and SAN FRANCISCO, Oct. 11, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that...
-
-- Demonstrated efficacy and safety consistent with global SOPHIA study-- Company expects to file BLA in China in advanced HER2+ breast cancer by approximately year end 2021 SHANGHAI and SAN...
-
SHANGHAI, China and SAN FRANCISCO, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) partner Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company...
-
Final data collection is expected in the first half of 2022 SHANGHAI and St. Helier, JERSEY, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative...
-
-- Expects to have more than 15 marketed products in more than 35 indications by 2025-- Aspires to become a leading global biopharmaceutical company SHANGHAI and SAN FRANCISCO, Sept. 22, 2021 ...